Drug
Tunlametinib PD 1 Mab
Tunlametinib PD 1 Mab: highest development phase Phase 2, developed by Sun Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Sun Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tunlametinib+PD-1 mAb NCT07507526 | Phase 2 | Gastric Adenocarcinoma |
Latest
No recent events.
Follow Tunlametinib PD 1 Mab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.